It's interesting, because I'm hearing from the Canadian Medical Association that they have tried to get this information and have been told that the word is “serious” adverse reactions. And that hasn't been defined, so they're in a quandary.
On that same issue, then, the biggest question of all on this issue is what are you going to do with all this information? Where are the extra staff and resources? There's nothing in the bill. It just says you're going to collect it. Where is it going to go? What's going to happen to it? Is it all going to go to Mr. Carleton? Or is it going to go to what's his name, the fellow at our committee last week who has a private company?
So to whom is this going?